TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: Together, the data presented here support the expectation that anti-CD30-MCC-DM1 may have clinically relevant efficacy in patients with HL, ALCL, and CTCL, who have cancer tissue with CD30 expression.